Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Carcinomatosis: Is HIPEC the Only Answer?
Read full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=52919#.VKydbcnQrzE Author(s) Ka-On Lam 1* , Betty Tsz-Ting Law 2 , Simon Ying-Kit Law 2 , Dora Lai-Wan Kwong 1 Affiliation(s) 1 Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China . 2 Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China . ABSTRACT <span "="">Gastric cancer with peritoneal carcinomatosis is notorious for its dismal prognosis. While the pathophysiology of peritoneal dissemination is still controversial, the rapid downhill course is universal. Patients usually suffer abdominal distension, intestinal obstruction and various complications before they succumb after a median of 3 - 6 months. Although not adopted in most international treatment guidelines, intraperitoneal chemotherapy has growing evidence compared with conventional...